- Details
- In this conversation Alicia Morgans, MD, MPH, and Ashley Ross, MD discuss his considerations of patient selection when using the oral GnRH antagonist, relugolix. Dr. Ross explains his thought process when considering oral ADT therapy for his patients, and outlines three specific scenarios when he leans into recommending its use for his patients and his approach to patient follow-up once oral treat...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Pedro Barata, MD, MSc, highlights two abstracts highlighting the importance of germline genetic testing in prostate cancer patients presented during the 2021 ASCO GU Cancers Symposium. Dr. Barata begins the abstract titled “ Landscape of Circulating Tumor DNA Abnormalities in Advanced Prostate Cancer: Distinctions Between African-American and Cauc...
|
- Details
- Prostate cancer and cardiovascular (CV) disease share several risk factors, with the incidence of both rising with increasing age. Systemic prostate cancer therapies may increase CV risk. In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight a recent paper published in Urologic Oncology: Seminars and Original Investigations titled " Androgen receptor inhibitor treatments...
|
- Details
- Cardiovascular disease and prostate cancer share several risk factors, with the incidence of both rising with increasing age. Systemic prostate cancer therapies may increase CV risk. In this conversation Oliver Sartor, MD, and Alicia Morgans, MD, MPH discuss the possibility of mitigating CV risk by appropriate selection of therapy and counseling patients related to their cardiovascular risk. They...
|
- Details
- Drs Alicia Morgans and Charles Ryan review advancements in the treatment in prostate cancer from 2020. Dr. Ryan first reviews the Phase 3 HERO study, Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer (ClinicalTrials.gov Identifier: NCT03085095), comparing relugolix, an oral gonadotropin-releasing hormone antagonist, to leuprolide in a 2:1 randomization which led to a very...
|
- Details
- Underinsured patients face significant barriers in accessing high‐quality care. “Access Denied: The Relationship Between Patient Insurance Status and Access to High‐volume Hospitals” studies the evidence of whether access to high‐volume surgical care is mediated by disparities in health insurance coverage. Quoc-Dien Trinh, an author of the study, joins Alicia Morgans to discuss his involvement in...
|
- Details
- Treatments in advanced prostate cancer continued to progress from research into clinical practice throughout 2020. Alicia Morgans, MD, MPH, and Charles Ryan, MD, discuss trials that matured, new drugs that were approved, and novel molecular imaging that transformed the prostate cancer treatment continuum. Biographies: Charles J. Ryan, MD , the President and Chief Executive Officer of The Prostate...
|
- Details
- Studies have historically underrepresented Black and non-White prostate cancer patients limiting our understanding of the disparities in the diagnosis and prognosis of prostate cancer among these populations. Brandon Mahal, MD, joins Charles Ryan, MD, to discuss what he reported in this New England Journal of Medicine paper titled "Racial Differences in Genomic Profiling of Prostate Cancer." Biogr...
|
- Details
- There are a number of trials looking at the role of adjuvant radiotherapy in prostate cancer. It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localized or locally advanced prostate cancer. In this Journal Club, Christopher Wallis, MD, Ph.D., and Zachary Klaassen, MD, MSc discuss the recent publication from th...
|
- Details
- Alicia Morgans, MD, MPH is joined by Felix Feng, MD, and Charles Ryan, MD in a conversation reflecting on their personal commitments to furthering the understanding and treatment of prostate cancer. The Month of September recognized as Prostate Cancer Awareness Month highlights the commitment each of them delivers every day of every month to their patients and to all prostate cancer patients aroun...
|
